362 related articles for article (PubMed ID: 20703489)
1. [IL-1 antagonists].
Kötter I; Horneff G
Z Rheumatol; 2010 Sep; 69(7):581-93. PubMed ID: 20703489
[TBL] [Abstract][Full Text] [Related]
2. Actual status of antiinterleukin-1 therapies in rheumatic diseases.
Geyer M; Müller-Ladner U
Curr Opin Rheumatol; 2010 May; 22(3):246-51. PubMed ID: 20150813
[TBL] [Abstract][Full Text] [Related]
3. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
[TBL] [Abstract][Full Text] [Related]
4. IL-1 blockade in autoinflammatory syndromes.
Jesus AA; Goldbach-Mansky R
Annu Rev Med; 2014; 65():223-44. PubMed ID: 24422572
[TBL] [Abstract][Full Text] [Related]
5. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.
Cavalli G; Dinarello CA
Rheumatology (Oxford); 2015 Dec; 54(12):2134-44. PubMed ID: 26209330
[TBL] [Abstract][Full Text] [Related]
6. Treating inflammation by blocking interleukin-1 in humans.
Dinarello CA; van der Meer JW
Semin Immunol; 2013 Dec; 25(6):469-84. PubMed ID: 24275598
[TBL] [Abstract][Full Text] [Related]
7. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Kalliolias GD; Liossis SN
Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Arnold DD; Yalamanoglu A; Boyman O
Front Immunol; 2022; 13():888392. PubMed ID: 35874710
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens.
Kuemmerle-Deschner JB; Wittkowski H; Tyrrell PN; Koetter I; Lohse P; Ummenhofer K; Reess F; Hansmann S; Koitschev A; Deuter C; Bialkowski A; Foell D; Benseler SM
Arthritis Res Ther; 2013; 15(3):R64. PubMed ID: 23718630
[TBL] [Abstract][Full Text] [Related]
10. [Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases].
Lipsker D; Lenormand C
Ann Dermatol Venereol; 2012 Jun; 139(6-7):459-67. PubMed ID: 22721478
[TBL] [Abstract][Full Text] [Related]
11. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
Landmann EC; Walker UA
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
[TBL] [Abstract][Full Text] [Related]
13. Blocking interleukin-1 in rheumatic diseases.
Goldbach-Mansky R
Ann N Y Acad Sci; 2009 Dec; 1182():111-23. PubMed ID: 20074280
[TBL] [Abstract][Full Text] [Related]
14. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
Toplak N; Blazina Š; Avčin T
Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
[TBL] [Abstract][Full Text] [Related]
15. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
16. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.
Dinarello CA; Simon A; van der Meer JW
Nat Rev Drug Discov; 2012 Aug; 11(8):633-52. PubMed ID: 22850787
[TBL] [Abstract][Full Text] [Related]
17. [CAPS treatment].
Jiménez Treviño S; Ramos Polo E
Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
[TBL] [Abstract][Full Text] [Related]
18. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
Rossi-Semerano L; Fautrel B; Wendling D; Hachulla E; Galeotti C; Semerano L; Touitou I; Koné-Paut I;
Orphanet J Rare Dis; 2015 Feb; 10():19. PubMed ID: 25758134
[TBL] [Abstract][Full Text] [Related]
19. The Future of IL-1 Targeting in Kidney Disease.
Afsar B; Covic A; Ortiz A; Afsar RE; Kanbay M
Drugs; 2018 Jul; 78(11):1073-1083. PubMed ID: 29968152
[TBL] [Abstract][Full Text] [Related]
20. Canakinumab for the treatment of adult-onset Still's disease.
Sfriso P; Bindoli S; Doria A; Feist E; Galozzi P
Expert Rev Clin Immunol; 2020 Feb; 16(2):129-138. PubMed ID: 31957508
[No Abstract] [Full Text] [Related]
[Next] [New Search]
